| Carl Eli Rosen, MD | |
|
542 W 2nd Ave, Anchorage, AK 99501-2208 | |
| (907) 276-1617 | |
| (907) 264-2687 |
| Full Name | Carl Eli Rosen |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 36 Years |
| Location | 542 W 2nd Ave, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306839873 | NPI | - | NPPES |
| MD1477 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | CR3386 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Alaska Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ophthalmic Associates A Professional Corporation | 4183515596 | 8 |
News Archive
The researchers found that MXC, which was manufactured as a safer replacement for the now-banned DDT, alters the estrogen-regulated gene Hoxa10 in the reproductive tract and reduces the ability of the uterus to support embryo implantation. The researchers used mice and then human cell lines to confirm their findings.
According to American researchers, brain scans of healthy people showed signs that the brain was shrinking in Alzheimer's-affected areas nearly a decade before the disease was diagnosed. This comes in the latest issue of the journal Neurology and it may offer a new way to detect the disease early, an advance that could help in the development of effective treatments for Alzheimer's, a brain-wasting disease that affects up to 26 million people globally.
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Princeton engineers have developed a sensor that may revolutionize how drugs and medical devices are tested for contamination, and in the process also help ensure the survival of two species of threatened animals.
› Verified 2 days ago
| Entity Name | Ophthalmic Associates A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255325692 PECOS PAC ID: 4183515596 Enrollment ID: O20040324000384 |
News Archive
The researchers found that MXC, which was manufactured as a safer replacement for the now-banned DDT, alters the estrogen-regulated gene Hoxa10 in the reproductive tract and reduces the ability of the uterus to support embryo implantation. The researchers used mice and then human cell lines to confirm their findings.
According to American researchers, brain scans of healthy people showed signs that the brain was shrinking in Alzheimer's-affected areas nearly a decade before the disease was diagnosed. This comes in the latest issue of the journal Neurology and it may offer a new way to detect the disease early, an advance that could help in the development of effective treatments for Alzheimer's, a brain-wasting disease that affects up to 26 million people globally.
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Princeton engineers have developed a sensor that may revolutionize how drugs and medical devices are tested for contamination, and in the process also help ensure the survival of two species of threatened animals.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carl Eli Rosen, MD 542 W 2nd Ave, Anchorage, AK 99501-2208 Ph: (907) 276-1617 | Carl Eli Rosen, MD 542 W 2nd Ave, Anchorage, AK 99501-2208 Ph: (907) 276-1617 |
News Archive
The researchers found that MXC, which was manufactured as a safer replacement for the now-banned DDT, alters the estrogen-regulated gene Hoxa10 in the reproductive tract and reduces the ability of the uterus to support embryo implantation. The researchers used mice and then human cell lines to confirm their findings.
According to American researchers, brain scans of healthy people showed signs that the brain was shrinking in Alzheimer's-affected areas nearly a decade before the disease was diagnosed. This comes in the latest issue of the journal Neurology and it may offer a new way to detect the disease early, an advance that could help in the development of effective treatments for Alzheimer's, a brain-wasting disease that affects up to 26 million people globally.
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Princeton engineers have developed a sensor that may revolutionize how drugs and medical devices are tested for contamination, and in the process also help ensure the survival of two species of threatened animals.
› Verified 2 days ago
James Patrick Ford, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-1400 | |
David Zumbro, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3500 Latouche St, Suite 250, Anchorage, AK 99508 Phone: 907-561-1530 | |
Dr. Richard Kevin Winkle, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3500 Latouche St Ste 280, Anchorage, AK 99508 Phone: 907-561-1917 | |
Julia D Shatten, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 542 W 2nd Ave, Anchorage, AK 99501 Phone: 907-276-1617 | |
Dr. James Richard Townley Iii, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-1162 | |
Elaine Rose Mcelhinny, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3801 University Lake Dr Fl 2, Anchorage, AK 99508 Phone: 646-506-3297 |